Media coverage about Heron Therapeutics (NASDAQ:HRTX) has been trending positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Heron Therapeutics earned a coverage optimism score of 0.26 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 47.0652899323654 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment’s rankings:
- Cantor Fitzgerald Names 8 Upcoming Biotech Catalysts – Benzinga (benzinga.com)
- Hot Stock’s Alert: Heron Therapeutics Inc (NASDAQ: HRTX) – Alpha Beta Stock (alphabetastock.com)
- Zacks: Brokerages Anticipate Heron Therapeutics Inc (HRTX) Will Announce Quarterly Sales of $10.92 Million (americanbankingnews.com)
- Heron Therapeutics Inc (HRTX) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- -$0.85 EPS Expected for Heron Therapeutics Inc (HRTX) This Quarter (americanbankingnews.com)
Heron Therapeutics (NASDAQ HRTX) traded down $1.85 during mid-day trading on Wednesday, hitting $22.20. 3,018,203 shares of the company traded hands, compared to its average volume of 923,278. Heron Therapeutics has a fifty-two week low of $12.70 and a fifty-two week high of $25.35. The firm has a market capitalization of $1,440.00, a P/E ratio of -6.08 and a beta of 1.87.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Tuesday, February 27th. The biotechnology company reported ($1.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.29). The firm had revenue of $10.05 million for the quarter, compared to the consensus estimate of $9.00 million. Heron Therapeutics had a negative return on equity of 230.70% and a negative net margin of 641.87%. analysts expect that Heron Therapeutics will post -2.56 EPS for the current year.
A number of equities analysts have recently commented on the stock. ValuEngine downgraded shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, March 1st. Cantor Fitzgerald set a $31.00 price objective on shares of Heron Therapeutics and gave the company a “buy” rating in a research report on Monday, January 15th. Leerink Swann began coverage on shares of Heron Therapeutics in a research report on Tuesday, January 2nd. They set an “outperform” rating and a $22.00 price target for the company. Lake Street Capital set a $42.00 price objective on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Friday, February 16th. Finally, BidaskClub upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, January 20th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. Heron Therapeutics has an average rating of “Buy” and an average price target of $30.08.
In related news, VP Kimberly Manhard sold 7,584 shares of the firm’s stock in a transaction that occurred on Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total value of $151,680.00. Following the completion of the transaction, the vice president now owns 7,584 shares in the company, valued at approximately $151,680. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 19.93% of the stock is owned by company insiders.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.